Advaxis, Inc. (NASDAQ:ADXS) shares reached a new 52-week high and low on Monday . The company traded as low as $1.60 and last traded at $1.58, with a volume of 485844 shares trading hands. The stock had previously closed at $1.69.
A number of research analysts have weighed in on ADXS shares. HC Wainwright set a $23.00 price target on Advaxis and gave the company a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $19.00 price target on Advaxis and gave the company a “buy” rating in a research note on Thursday, December 28th. Finally, ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
The company has a market cap of $88.41, a price-to-earnings ratio of -0.69 and a beta of 1.19.
Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%. The company had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million. equities research analysts predict that Advaxis, Inc. will post -1.73 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Renaissance Technologies LLC acquired a new stake in shares of Advaxis in the fourth quarter valued at approximately $1,398,000. Deutsche Bank AG lifted its position in shares of Advaxis by 1,200.1% in the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after buying an additional 431,379 shares during the last quarter. Bank of Montreal Can lifted its position in shares of Advaxis by 16,465.9% in the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock valued at $1,230,000 after buying an additional 430,583 shares during the last quarter. Franklin Street Advisors Inc. NC lifted its position in shares of Advaxis by 117.1% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 70,000 shares during the last quarter. Finally, Capital Analysts LLC lifted its position in shares of Advaxis by 2,214.3% in the fourth quarter. Capital Analysts LLC now owns 69,428 shares of the biotechnology company’s stock valued at $3,962,000 after buying an additional 66,428 shares during the last quarter. 29.13% of the stock is owned by institutional investors.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.